<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151258">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790789</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0027</org_study_id>
    <secondary_id>OS12706</secondary_id>
    <nct_id>NCT01790789</nct_id>
  </id_info>
  <brief_title>Stress Reduction in Ovarian Cancer</brief_title>
  <official_title>Stress Reduction During Primary Adjuvant Chemotherapy for Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of a stress reduction program on the
      quality of life of ovarian cancer patients during primary adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>18 weeks (completion of chemotherapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fatigue will be measured using the NIH PROMIS Cancer Fatigue survey instrument</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Natural Killer Cell Activity</measure>
    <time_frame>18 weeks (completion of chemotherapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cytotoxicity assays will be conducted to determine if the meditation-based intervention results in an increase in the ability of the NK cells to recognize and lyse cancer targets.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ovarian, Fallopian, and Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Stress reduction program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Daily stress reduction program</intervention_name>
    <description>Subjects will participate in activities of a daily stress reduction program.</description>
    <arm_group_label>Stress reduction program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Attention control</intervention_name>
    <description>Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.</description>
    <arm_group_label>Attention control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have an initial diagnosis of ovarian, fallopian tube or primary
             peritoneal cancer who completed primary ovarian cancer surgery or 3 cycles of
             neoadjuvant chemotherapy with interval cytoreductive surgery (ICS).

          -  Final pathology diagnosis of stage I-IV ovarian, fallopian tube or primary peritoneal
             cancer with plan to receive primary adjuvant chemotherapy or completion of
             chemotherapy after ICS.

          -  Receive chemotherapy at the University of Wisconsin-Madison.

          -  Subjects must be at least 18 years of age.

          -  English-speaking

          -  Subjects must be able to use audio media, and read and understand the study manual.

          -  ECOG performance status 0-2.

          -  Subjects must have a phone.

        Exclusion Criteria:

          -  Subjects participating in a meditation practice more than 1 hour per week prior to
             surgery and/or chemotherapy administration.

          -  Subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer.

          -  Subjects with diagnosis of Chronic Fatigue Syndrome (CFS).

          -  Subjects unable to use audio media due to auditory dysfunction.

          -  Subjects unable to read written English.

          -  Subjects who are prisoners or incarcerated.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Rose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Connect</last_name>
    <phone>800-622-8922</phone>
    <email>cancerconnect@uwcarbone.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Stewart</last_name>
    <phone>608-263-0796</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Connect</last_name>
      <phone>800-622-8922</phone>
    </contact>
    <contact_backup>
      <last_name>Sarah Stewart</last_name>
      <phone>608-263-0796</phone>
    </contact_backup>
    <investigator>
      <last_name>Stephen Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryan Spencer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
